Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

NCT04297605 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Pembrolizumab
OTHER: Pemetrexed (Chemotherapy)
OTHER: Nab-paclitaxel (Chemotherapy)

Sponsor

University of Rochester